# US 2024/0201185 A1 · Markers of autoimmune diseases

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0201185 A1
- Document ID: US20240201185A1
- Status: Published application
- Kind: A1
- Application number: 18/556,496
- Filed: 2022-04-21
- Published: 2024-06-20
- Earliest claimed: 2021-04-21
- Assignees: Sorbonne Universite; Institut National De La Sante Et De La Recherche Medicale (Inserm); Assistance Publique-Hopitaux de Paris
- Applicants: Sorbonne Universite; Institut National De La Sante Et De La Recherche Medicale (Inserm); Assistance Publique – Hopitaux De Paris
- Inventors: Cindy MARQUES; Paul REGNIER; David SAADOUN
- Web page: https://patentgrep.com/patent/US20240201185A1

## CPC

- G01N 33/564: for pre-existing immune complex or autoimmune disease {, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9}
- G01N 33/56972: {White blood cells}
- G01N 33/57505: of the blood, e.g. leukaemia
- G01N 33/57557: {of other specific parts of the body, e.g. brain}
- G01N 2333/70553: Integrin beta2-subunit-containing molecules, e.g. CD11, CD18
- G01N 2333/70578: NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30 CD40 or CD95
- G01N 2333/70596: Molecules with a "CD"-designation not provided for elsewhere in G01N2333/705
- G01N 2333/7158: for chemokines
- G01N 2800/101: Diffuse connective tissue disease, e.g. Sjögren, Wegener's granulomatosis
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

The present invention is directed to methods of diagnosis and treatment of autoimmune, chronic inflammatory and lymphoproliferative diseases based on the identification of a population of pathogenic B and/or T cells showing a specific phenotype. These cells may be identified by their specific pattern of expression of marker proteins.

## Claims

### Claim 1

A method of diagnosing of pSS, L-pSS and lymphoma in a subject, comprising obtaining a test sample from the subject and detecting the presence of pathogenic B cells in the test sample, that express the marker proteins CD19, CD27, CD21, CD11c, CXCR5, and optionally at least one marker protein selected in the group consisting of Tbet, CD95, FCRL3, FCRL5, IgM, IgD, CD24, CD38 and/or G6 at a different level compared to a baseline level established from a healthy donor sample and wherein the presence of said pathogenic B cells in the sample, identifies the subject as having or likely to develop the autoimmune disease or a lymphoproliferative form or a chronic inflammatory form of an autoimmune disease.

### Claim 2 (depends on 1)

The method of claim 1, wherein the expression of marker proteins, for those detected, is as follows:
Variation from
Marker proteins
Level of expression
healthy donors (%)
CD19
High
about +50%
CD27
Low
about −30%
CD21
Low
about −15%
CD11c
High to very high
about +50%
CXCR5
high
about +5%

### Claim 3

A method for an in vitro detection of pathogenic B cells, the method comprising: detecting CD19, CD27, CD21, CD11c, and CXCR5, and optionally at least one marker protein selected from the group consisting of: Tbet, CD95, FCRL3, FCRL5, IgM, IgD, CD24, CD38 and G6, as markers for the in vitro detection of pathogenic B cells.

### Claim 4

A method of detection of pathogenic B cells in a subject, comprising obtaining a biological sample from the subject and determining the level of cellular expression of CD19, CD27, CD21, CD11c, CXCR5, and optionally at least one marker protein selected in the group consisting of Tbet, CD95 and/or FCRL3, wherein expression CD19+CD27− CD21− CD11c++ CXCR5+ Tbet++CD95+ FCRL3+ for the markers for which the level cellular expression has been determined is indicative of pathogenic B cells.

### Claim 5

An in vitro detection method of pathogenic B cells in a biological sample from a patient comprising the steps of:
(i) determining the level of cellular expression of CD19, CD27, CD21, CD11c, CXCR5, and optionally at least one marker protein selected in the group consisting of Tbet, CD95 and/or FCRL3 of B cells in the biological sample;
(ii) in vitro detection of the expression CD19+CD27− CD21− CD11c++ CXCR5+ Tbet++CD95+ FCRL3+ in B cells from the biological sample, for the markers for which the level cellular expression has been determined, the detection of this expression denoting the presence of pathogenic B cells in the biological sample.

### Claim 6

A kit for the diagnosis of pSS, L-pSS and lymphoma in a subject or for the detection of pathogenic B cells, comprising reagents, each being used to determine the expression level of one of the marker proteins CD19, CD27, CD21, CD11c, CXCR5, and optionally Tbet, CD95, FCRL3, FCRL5, IgM, IgD, CD24, CD38 and/or G6 in a sample.

### Claim 7

A method to evaluate the efficacy of a treatment of an autoimmune disease or a lymphoproliferative form or a chronic inflammatory form of an autoimmune disease in a subject, comprising determining the expression of marker proteins CD19, CD27, CD21, CD11c, CXCR5, and optionally at least one marker protein selected in the group consisting of Tbet, CD95, FCRL3, FCRL5, IgM, IgD, CD24, CD38 and/or G6 in B cells in a sample taken from the subject before administering the treatment; detecting the presence of pathogenic B cells in a sample taken from the subject after administering the treatment; and comparing the level of expression of said marker proteins in the sample taken from the subject before administering the treatment to the level expression of said marker proteins in the sample taken from the subject after administering the treatment.

### Claim at position 8

8-16. (canceled)

### Claim 17 (depends on 1)

The method of claim 1, comprising obtaining a test sample from said subject and detecting the presence of pathogenic T cells in the test sample, that express the marker proteins selected amongst: CD3+CD4+ TNFα+ CXCR3− CCR6− IL-21− CXCR5− IL-17− IL-4− IFNγ+ or − in T cells.

### Claim 18 (depends on 7)

The kit according to claim 7, comprising additional reagents, each being used to determine the expression level of one of the marker proteins: CD3 CD4 TNFα CXCR3 CCR6 IL-21 CXCR5 IL-17 IL-4 IFNγ in T cells; in a sample.
